# USC-UCLA Drug-Induced Liver Injury (DILI) Clinical Center

> **NIH NIH U01** · UNIVERSITY OF SOUTHERN CALIFORNIA · 2024 · $346,560

## Abstract

The USC-UCLA Drug-Induced Liver Injury Clinical Center (CC) proposal in response to RFA-DK-22-013
“Continuation of the Drug Induced Liver Injury Network (DILIN) Clinical Centers” hopes to continue to participate
with the other CCs to advance the scientific knowledge and clinical evaluation of DILI. Our proposal will continue
to combine the only two medical schools in Los Angeles County allowing us to be able to uniquely capture and
enroll DILI cases into the Networks database supervised by the Data Coordinating Center (DCC). The 9.8 M
residents of Los Angeles County (2022) are an unmatched resource composed of the most ethnically diverse
population in the United States. Our proposal continues to utilize the expertise and talents from Keck School of
Medicine of USC and David Geffen School of Medicine at UCLA. The enrollment of a large number of bona fide
and ill patients with close follow up has demonstrated our CC’s ability to capture DILIN cases in this diverse
populations with little overlap in etiology for DILI other than for herbal and dietary supplements (HDS) in our
respective patient populations. The Specific Aims for the continuation of the USC-UCLA DILI CC are to: 1)
Continued enrollment of high quality bona fide DILI case from under represented populations and HDS agents
with proposed biospecimens collections for future studies.; 2) Specific Aim 2: Mechanism of cell death and the
role of innate immunity in Immune-Mediated Liver Injury due to Checkpoint Inhibitors (ILICI) (Ancillary Study); 3)
Specific Aim 3: Proposed Clinical Treatment Trial for Cholestatic and Acute Liver Injury and 4) Specific Aim 4:
Continued support of the DILIN’s effort to develop causality assessment instruments and development of a pilot
project for a pharmacovigilance protocol for adverse liver injury due to medication or HDS.
.

## Key facts

- **NIH application ID:** 10918220
- **Project number:** 5U01DK083020-17
- **Recipient organization:** UNIVERSITY OF SOUTHERN CALIFORNIA
- **Principal Investigator:** ANDREW Abba STOLZ
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $346,560
- **Award type:** 5
- **Project period:** 2008-09-30 → 2028-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10918220

## Citation

> US National Institutes of Health, RePORTER application 10918220, USC-UCLA Drug-Induced Liver Injury (DILI) Clinical Center (5U01DK083020-17). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10918220. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*